Abstract:Two series of new pyridyl-bearing fused bicyclic analogues designed to target the dual-tolerant regions of the non-nucleoside reverse transcriptase inhibitor (NNRTI)-binding pocket were synthesized and evaluated for their anti-HIV activities. Several compounds, such as 6, 14, 15, 21, 30, and 33, were found to be potent inhibitors against the wild-type (WT) HIV-1 strain or multiple NNRTI-resistant strains at low nanomolar levels. Detailed structure–activity relationships were obtained by utilizing the variation of moieties within the corresponding pharmacophores. In vitro metabolic stability profiles and some drug-like properties of selected compounds were assessed, furnishing the preliminary structure–metabolic stability relationships. Furthermore, molecular modeling studies elucidated the binding modes of compounds 6, 15, 21, and 30 in the binding pocket of WT, E138K, K103N, or Y181C HIV-1 RTs. These promising compounds can be used as lead compounds and warrant further structural optimization to yield more active HIV-1 inhibitors.The Supporting Information is available free of charge at https://pubs.acs.org/doi/10.1021/acs.jmedchem.1c00987.Molecular formula strings (CSV)In vitro anti-HIV assays in MT-4 cells; WT HIV-1 RT inhibition assays; metabolic stability assays in human liver microsomes; molecular modeling; predicted miLogP and MolLogP values of target compounds and controls; mean distance and standard deviation values for selected ligand–protein contacts in simulated systems; regression analysis of miLogP values and MolLogP values; rmsd profiles for the protein backbone, NNRTI-binding site, and simulated inhibitors for the RT-inhibitor complexes; time-dependent distance distribution for d1–d4 for RT-inhibitor complexes; representation of the molecular interaction potential for the interaction of compounds 6, 15, 21, and 30 with a positively and a negatively charged atom; and 1H NMR, 13C NMR, and ESI-MS spectra for the target compounds (PDF).This article has not yet been cited by other publications.

Arylazolyl(azinyl)thioacetanilides. Part 16: Structure-based bioisosterism design, synthesis and biological evaluation of novel pyrimidinylthioacetanilides as potent HIV-1 inhibitors.

Arylazolyl(azinyl)thioacetanilides. Part 10: design, synthesis and biological evaluation of novel substituted imidazopyridinylthioacetanilides as potent HIV-1 inhibitors.

Arylazolylthioacetanilide. Part 8☆: Design, Synthesis and Biological Evaluation of Novel 2-(2-(2,4-dichlorophenyl)-2h-1,2,4-triazol-3-ylthio)-n-arylacetamides As Potent HIV-1 Inhibitors

Arylazolyl(azinyl)thioacetanilides: Part 19: Discovery of Novel Substituted Imidazo[4,5-b]pyridin-2-ylthioacetanilides as Potent HIV NNRTIs Via a Structure-based Bioisosterism Approach.

Arylazolyl(azinyl)thioacetanilides. Part 20: Discovery of Novel Purinylthioacetanilides Derivatives As Potent HIV-1 NNRTIs Via a Structure-Based Bioisosterism Approach

Structure-Based Bioisosterism Design, Synthesis and Biological Evaluation of Novel 1,2,4-Triazin-6-ylthioacetamides As Potent Hiv-1 Nnrtis

Arylazolylthioacetanilide. Part 11: Design, Synthesis and Biological Evaluation of 1,2,4-Triazole Thioacetanilide Derivatives As Novel Non-Nucleoside HIV-1 Reverse Transcriptase Inhibitors.

Discovery of Novel 2-(3-(2-chlorophenyl)pyrazin-2-ylthio)-n-arylacetamides As Potent Hiv-1 Inhibitors Using A Structure-Based Bioisosterism Approach

Design, Synthesis, and Biological Evaluation of Novel 5-Alkyl-6-adamantylmethylpyrimidin-4(3h)-ones As Hiv-1 Non-Nucleoside Reverse-Transcriptase Inhibitors

Synthesis and biological evaluation of pyridazine derivatives as novel HIV-1 NNRTIs.

Design, Synthesis, and Biological Evaluation of Novel 2‐(pyridin‐3‐yloxy)acetamide Derivatives As Potential Anti‐HIV‐1 Agents

Design, Synthesis and Biological Evaluation of 3-Benzyloxy-linked Pyrimidinylphenylamine Derivatives As Potent HIV-1 NNRTIs.

Discovery of Novel Pyridazinylthioacetamides As Potent Hiv-1 Nnrtis Using A Structure-Based Bioisosterism Approach

1,2,3-thiadiazole thioacetanilides. Part 2: Synthesis and biological evaluation of a new series of 2-{[4-(3,4-dichlorophenyl)-1,2,3-thiadiazol-5-yl]sulfanyl}acetanilides as HIV-1 inhibitors.

Structure-Based Design and Discovery of Pyridyl-Bearing Fused Bicyclic HIV-1 Inhibitors: Synthesis, Biological Characterization, and Molecular Modeling Studies

Synthesis and Anti-HIV-1 Activity Evaluation for Novel 3a,6a-Dihydro-1H-pyrrolo[3,4-c]pyrazole-4,6-dione Derivatives.

Synthesis and Anti-Hiv Activity Evaluation of 2-(5-(naphthalen-1-yl)-1,2,3-thiadiazol-4-ylthio)-n-acetamides Derivatives

Synthesis and Biological Evaluation of 6‐substituted 5‐alkyl‐2‐(phenylaminocarbonylmethylthio)pyrimidin‐4(3h)‐ones As Potent HIV‐1 NNRTIs

Synthesis and Biological Evaluation of a Series of 2-(((5-akly/aryl-1h-pyrazol-3-yl)methyl)thio)-5-alkyl-6-(cyclohexylmethyl)-pyrimidin-4(3h)-ones As Potential HIV-1 Inhibitors.

Synthesis and biological evaluation of novel 2-arylalkylthio-4-amino-6-benzyl pyrimidines as potent HIV-1 non-nucleoside reverse transcriptase inhibitors.

Design, Synthesis, and Biological Evaluation of Novel Benzoyl Diarylamine/ether Derivatives as Potential Anti-HIV-1 Agents.